| Literature DB >> 33217343 |
David A Wheeler1, Naoko Takebe2, Toshinori Hinoue3, Katherine A Hoadley4, Maria F Cardenas1, Alina M Hamilton4, Peter W Laird3, Linghua Wang5, Adrienne Johnson6, Ninad Dewal6, Vincent Miller6, David Piñeyro7, Manuel Castro de Moura8, Manel Esteller9, Hui Shen3, Jean Claude Zenklusen10, Roy Tarnuzzer10, Lisa M McShane2, James V Tricoli2, Paul M Williams11, Irina Lubensky2, Geraldine O'Sullivan-Coyne2, Elise C Kohn2, Richard F Little2, Jeffrey White2, Shakun Malik2, Lyndsay Harris2, Carol Weil2, Alice P Chen2, Chris Karlovich11, Brian Rodgers2, Lalitha Shankar2, Paula Jacobs2, Tracy Nolan12, Jianhong Hu13, Donna M Muzny13, Harshavardhan Doddapaneni13, Viktoriya Korchina13, Julie Gastier-Foster14, Jay Bowen14, Kristen Leraas14, Elijah F Edmondson15, James H Doroshow2, Barbara A Conley2, S Percy Ivy2, Louis M Staudt16.
Abstract
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories-DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis-with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy. Published by Elsevier Inc.Entities:
Keywords: DNA methylation analysis; DNA repair mechanisms; N of 1 experiment; RNA sequencing; combination cancer therapy; exceptional response to therapy; integrating molecular and clinical data; multi-platform genomic analyses; precision cancer medicine; rare mutations; synthetic lethality; whole-exome sequencing
Mesh:
Substances:
Year: 2020 PMID: 33217343 PMCID: PMC8478080 DOI: 10.1016/j.ccell.2020.10.015
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743